• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Prognostic value of BRCA1 mutations in familial breast cancer patients affected by a second primary cancer.

作者信息

Elsakov Pavel, Kurtinaitis Juozas, Ostapenko Valerij

机构信息

Institute of Oncology, Vilnius University, Santariskiu 1str, Vilnius, Lithuania.

出版信息

Fam Cancer. 2007;6(4):409-13. doi: 10.1007/s10689-007-9139-7. Epub 2007 May 23.

DOI:10.1007/s10689-007-9139-7
PMID:17520345
Abstract

The aim of this prospective study is to assess the prognostic value of BRCA1 mutations in familial breast cancer patients affected by a second primary cancer. The study group comprised 19 women having multiple primary breast cancers (breast-breast, breast-other primary) who were either BRCA1 mutation carriers, or not. Appearance of a second primary cancer was recognised as the event and survival and second primary free cancer survival was calculated from the date of diagnosis to the secondary primary cancer. The results of this study show that the event free survival of women with familial breast cancer affected by a second primary cancer, who are BRCA1 mutation carriers is better, compared with women from the general population with breast cancer selected for second primary cancer sites and all second primary sites -- P = 0.009 and P = 0.0078 respectively. In contrast, the event free survival of women with breast cancer affected by a second primary cancer, without a breast cancer family history, who are not BRCA1 mutation carriers is the same, as for women from the general population with breast cancer selected for second primary cancer sites and all second primary sites -- P = 0.6417 and P = 0.4859 respectively. The median time from diagnosis of the first to second primary cancer in the mutation carrying, and non-carrying, groups was 8,7 and 1,9 years respectively. In the study group, the highest event free survival rates had been observed among those carrying the said mutations -- 66.7% at 5 years, and 33.3% at 10 years -- in contrast with those not carrying the mutations, with rates of 30.8% and 15.4% respectively.

摘要

相似文献

1
Prognostic value of BRCA1 mutations in familial breast cancer patients affected by a second primary cancer.
Fam Cancer. 2007;6(4):409-13. doi: 10.1007/s10689-007-9139-7. Epub 2007 May 23.
2
Impact of Age at Primary Breast Cancer on Contralateral Breast Cancer Risk in BRCA1/2 Mutation Carriers.BRCA1/2 基因突变携带者中初次乳腺癌发病年龄对侧乳腺癌风险的影响。
J Clin Oncol. 2016 Feb 10;34(5):409-18. doi: 10.1200/JCO.2015.62.3942. Epub 2015 Dec 23.
3
Pathologic characteristics of breast parenchyma in patients with hereditary breast carcinoma, including BRCA1 and BRCA2 mutation carriers.遗传性乳腺癌患者乳腺实质的病理特征,包括BRCA1和BRCA2突变携带者。
Cancer. 2003 Jan 1;97(1):1-11. doi: 10.1002/cncr.11048.
4
Ovarian cancer risk in Ashkenazi Jewish carriers of BRCA1 and BRCA2 mutations.携带BRCA1和BRCA2突变的阿什肯纳兹犹太女性患卵巢癌的风险。
Clin Cancer Res. 2002 Dec;8(12):3776-81.
5
Effect of Oophorectomy on Survival After Breast Cancer in BRCA1 and BRCA2 Mutation Carriers.BRCA1 和 BRCA2 基因突变携带者乳腺癌术后卵巢切除术对生存的影响。
JAMA Oncol. 2015 Jun;1(3):306-13. doi: 10.1001/jamaoncol.2015.0658.
6
Pathology of familial breast cancer: differences between breast cancers in carriers of BRCA1 or BRCA2 mutations and sporadic cases. Breast Cancer Linkage Consortium.家族性乳腺癌的病理学:BRCA1或BRCA2突变携带者的乳腺癌与散发性病例之间的差异。乳腺癌连锁协会。
Lancet. 1997 May 24;349(9064):1505-10.
7
Contralateral breast cancer risk in BRCA1 and BRCA2 mutation carriers.携带BRCA1和BRCA2基因突变者的对侧乳腺癌风险。
J Clin Oncol. 2009 Dec 10;27(35):5887-92. doi: 10.1200/JCO.2008.19.9430. Epub 2009 Oct 26.
8
Contralateral recurrence and prognostic factors in familial non-BRCA1/2-associated breast cancer.家族性非BRCA1/2相关乳腺癌的对侧复发及预后因素
Br J Surg. 2006 Aug;93(8):961-8. doi: 10.1002/bjs.5344.
9
Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.预防性卵巢切除术:降低美国上皮性卵巢癌死亡率。一场持续的争论。
Oncologist. 1996;1(5):326-330.
10
Is the breast-conserving treatment with radiotherapy appropriate in BRCA1/2 mutation carriers? Long-term results and review of the literature.保乳治疗联合放疗是否适用于 BRCA1/2 突变携带者?长期结果及文献复习。
Breast Cancer Res Treat. 2010 Feb;120(1):119-26. doi: 10.1007/s10549-009-0685-6. Epub 2009 Dec 24.

引用本文的文献

1
Clinical and Functional Assays of Radiosensitivity and Radiation-Induced Second Cancer.放射敏感性和辐射诱发的二次癌症的临床与功能测定
Cancers (Basel). 2017 Oct 27;9(11):147. doi: 10.3390/cancers9110147.

本文引用的文献

1
High incidence of 4153delA BRCA1 gene mutations in Lithuanian breast- and breast-ovarian cancer families.立陶宛乳腺癌和乳腺-卵巢癌家族中4153delA BRCA1基因突变的高发生率。
Breast Cancer Res Treat. 2005 Nov;94(2):111-3. doi: 10.1007/s10549-005-5150-6.
2
High prevalence of two BRCA1 mutations, 4154delA and 5382insC, in Latvia.拉脱维亚两种BRCA1突变(4154delA和5382insC)的高流行率。
Fam Cancer. 2005;4(2):77-84. doi: 10.1007/s10689-004-2758-3.
3
A high proportion of founder BRCA1 mutations in Polish breast cancer families.
波兰乳腺癌家族中高比例的始祖BRCA1突变。
Int J Cancer. 2004 Jul 10;110(5):683-6. doi: 10.1002/ijc.20162.
4
Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status.根据BRCA1/2状态对早期乳腺癌进行保守治疗的结果。
Lancet. 2002 Apr 27;359(9316):1471-7. doi: 10.1016/S0140-6736(02)08434-9.
5
Founder mutations in the BRCA1 gene in west Belarusian breast-ovarian cancer families.白俄罗斯西部乳腺癌-卵巢癌家族中BRCA1基因的奠基者突变
Clin Genet. 2001 Dec;60(6):470-1. doi: 10.1034/j.1399-0004.2001.600611.x.
6
Cancer risks in women with 2 breast or ovarian cancers: clues to genetic cancer susceptibility.患有两种乳腺癌或卵巢癌的女性的癌症风险:遗传性癌症易感性线索
Int J Cancer. 2001 Dec 1;94(5):758-9. doi: 10.1002/ijc.1534.
7
BRCA1 and BRCA2 mutations in breast cancer families with multiple primary cancers.患有多原发性癌症的乳腺癌家族中的BRCA1和BRCA2突变
Clin Cancer Res. 2000 Nov;6(11):4259-64.
8
Prevalence and penetrance of BRCA1 and BRCA2 mutations in a population-based series of breast cancer cases. Anglian Breast Cancer Study Group.基于人群的一系列乳腺癌病例中BRCA1和BRCA2突变的患病率及外显率。东安格利亚乳腺癌研究小组。
Br J Cancer. 2000 Nov;83(10):1301-8. doi: 10.1054/bjoc.2000.1407.
9
Familial cancer risks to offspring from mothers with 2 primary breast cancers: leads to cancer syndromes.患有2种原发性乳腺癌的母亲传给后代的家族性癌症风险:导致癌症综合征。
Int J Cancer. 2000 Oct 1;88(1):87-91. doi: 10.1002/1097-0215(20001001)88:1<87::aid-ijc14>3.0.co;2-f.
10
Breast conservation therapy for invasive breast cancer in Ashkenazi women with BRCA gene founder mutations.对携带BRCA基因始祖突变的德系犹太女性浸润性乳腺癌患者进行保乳治疗。
J Natl Cancer Inst. 1999 Dec 15;91(24):2112-7. doi: 10.1093/jnci/91.24.2112.